Curran Monique P, Wagstaff Antona J
Adis International Limited, 41 Centorian Drive, PB 65901, Mairangi Bay, Auckland, New Zealand.
Drugs. 2004;64(7):751-60; discussion 761-2. doi: 10.2165/00003495-200464070-00005.
Ethinylestradiol/chlormadinone acetate 0.03/2mg (EE/CMA) is a combined monophasic contraceptive pill with antiandrogenic properties. In a large, noncomparative, multicentre trial (< or =24 cycles of treatment per woman) and two (6- and 12-cycle) postmarketing surveillance studies, EE/CMA was effective in preventing pregnancy. EE/CMA was significantly more effective than EE/levonorgestrel 0.03/0.15 mg/day in treating women with mild-to-moderate papulopustular acne of the face and related disorders in a randomised, single-blind, multicentre trial. EE/CMA was well tolerated in clinical trials and the postmarketing surveillance studies. Adverse events were those commonly reported with oral contraceptives. As expected, the most common menstrual disturbances were breakthrough bleeding, spotting and amenorrhoea.
炔雌醇/醋酸氯地孕酮0.03/2毫克（EE/CMA）是一种具有抗雄激素特性的复方单相避孕药。在一项大型、非对照、多中心试验（每位女性治疗≤24个周期）以及两项上市后监测研究（6周期和12周期）中，EE/CMA在预防妊娠方面有效。在一项随机、单盲、多中心试验中，EE/CMA在治疗面部轻至中度丘疹脓疱性痤疮及相关病症方面比炔雌醇/左炔诺孕酮0.03/0.15毫克/天显著更有效。EE/CMA在临床试验和上市后监测研究中耐受性良好。不良事件为口服避孕药常见的报告事件。正如预期的那样，最常见的月经紊乱为突破性出血、点滴出血和闭经。
